De La Fuente R, Sonawane N D, Arumainayagam D, Verkman A S
Department of Medicine, Cardiovascular Research Institute, University of California, San Francisco, CA 94143-0521, USA.
Br J Pharmacol. 2006 Nov;149(5):551-9. doi: 10.1038/sj.bjp.0706873. Epub 2006 Sep 18.
New antimicrobials are needed because of the emergence of organisms that are resistant to available antimicrobials. The purpose of this study was to evaluate a high-throughput screening approach to identify antibacterials against two common disease-causing bacteria, and to determine the frequency, novelty, and potency of compounds with antibacterial activity.
A high-throughput, turbidometric assay of bacterial growth in a 96-well plate format was used to screen a diverse collection of 150,000 small molecules for antibacterial activity against E. coli and P. aeruginosa. The statistical Z'-factor for the assay was > or = 0.7.
Screening for inhibition of E. coli growth gave a 'hit' rate (> 60% inhibition at 12.5 microM) of 0.025%, which was more than 5-fold reduced for P. aeruginosa. The most potent antibacterials (EC50 < 0.5 microM) were of the nitrofuran class followed by naphthalimide, salicylanilide, bipyridinium and quinoazolinediamine chemical classes. Screening of > 250 analogs of the most potent antibacterial classes established structure-activity data sets.
Our results validate and demonstrate the utility of a growth-based phenotype screen for rapid identification of small-molecule antibacterials. The favourable efficacy and structure-activity data for several of the antibacterial classes suggests their potential development for clinical use.
由于出现了对现有抗菌药物耐药的微生物,因此需要新的抗菌药物。本研究的目的是评估一种高通量筛选方法,以鉴定针对两种常见致病细菌的抗菌药物,并确定具有抗菌活性的化合物的频率、新颖性和效力。
采用96孔板形式的细菌生长高通量比浊法,筛选150,000种小分子的多样化集合,以检测其对大肠杆菌和铜绿假单胞菌的抗菌活性。该检测的统计Z'因子≥0.7。
筛选抑制大肠杆菌生长的“命中”率(在12.5 microM时抑制率>60%)为0.025%,对铜绿假单胞菌的抑制率降低了5倍以上。最有效的抗菌药物(EC50<0.5 microM)为硝基呋喃类,其次是萘酰亚胺、水杨酰苯胺、联吡啶鎓和喹唑啉二胺化学类。对最有效的抗菌类别的>250种类似物进行筛选,建立了构效数据集。
我们的结果验证并证明了基于生长的表型筛选在快速鉴定小分子抗菌药物方面的实用性。几种抗菌类别的良好疗效和构效数据表明它们具有临床应用的潜在开发价值。